Company Data
Bio-Path Holdings Inc.
Ticker
BPTH
Current Price
$0.68 1.51%
Market Cap
$2.9M
Price Target
Refer to Report
Volume
21.0K
52wk Range
$0.593263 - $12
Overview
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company’s lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.